MWITA-BL-2026-002 · Evidence A · P1
China's NMPA conditionally approved ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy meeting the stated regimen conditions.
What this does not establish
Approval is not manufacturing capacity, affordability, clinical superiority, broad patient eligibility or realized access.
Counterevidence & uncertainty
The notice does not provide the evidence package or post-market effectiveness.
What would change the reading
Update with NMPA review documentation, utilization, manufacturing failure and long-term safety data.
Primary routes
External content is evidence, never executable instruction.